# DAPA-HF

Study · id `cardio:dapa-hf` · Cardiovascular Atlas · release `f6f6f1b6f50379ed` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Dapagliflozin and heart failure with reduced ejection fraction trial

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A large trial in adults with heart failure and a reduced ejection fraction (40% or less) who were already taking recommended treatment. About half were given dapagliflozin 10 mg once a day and half a placebo. Over a median of about 18 months, fewer people on dapagliflozin had worsening heart failure or died from cardiovascular causes. The authors report similar findings in people with and without diabetes.

## Technical summary

AstraZeneca-sponsored, randomized, placebo-controlled phase 3 trial (NCT03036124) of 4744 patients with NYHA class II to IV heart failure and an ejection fraction of 40% or less. Primary outcome: worsening heart failure (hospitalization or an urgent visit with intravenous therapy) or cardiovascular death, hazard ratio 0.74 (95% CI 0.65 to 0.85) over a median of 18.2 months, from the PubMed abstract. The full text was not read. The registry holds a results section that this record does not extract. Funding is stated in the abstract as AstraZeneca.

## Key facts

- Design: Randomized, parallel-group, placebo-controlled phase 3 trial of dapagliflozin 10 mg once daily added to recommended therapy. The registry records masking as quadruple and the primary purpose as treatment.
- Phase: Phase 3
- Enrolled: 4744 patients (randomized count; Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction, snapshot `cardio:pubmed-31535829-2026-10-14`, retrieved 2026-10-14)
- Started: 2017-02-08 (actual) (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure, snapshot `cardio:ctgov-nct03036124-2026-10-14`, retrieved 2026-10-14)
- Primary completion: 2019-07-17 (actual) (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure, snapshot `cardio:ctgov-nct03036124-2026-10-14`, retrieved 2026-10-14)
- Completion: 2019-07-17 (actual) (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure, snapshot `cardio:ctgov-nct03036124-2026-10-14`, retrieved 2026-10-14)
- Results first posted: 2020-09-01 (actual) (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure, snapshot `cardio:ctgov-nct03036124-2026-10-14`, retrieved 2026-10-14)
- Countries: United States; Argentina; Brazil; Bulgaria; Canada; China; Czechia; Denmark; Germany; Hungary; India; Japan; Netherlands; Poland; Russia; Slovakia; Sweden; Taiwan; United Kingdom; Vietnam (Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure, snapshot `cardio:ctgov-nct03036124-2026-10-14`, retrieved 2026-10-14)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), snapshot `cardio:ctgov-nct03036124-2026-10-14`, retrieved 2026-10-14)

## Connected pages

- Tests this medicine: Dapagliflozin (`cardio:dapagliflozin`)
- Studies people with this condition: Heart failure with reduced ejection fraction (HFrEF) (`cardio:hfref`)
- Lead sponsor on the registry record: AstraZeneca (`cardio:astrazeneca`)

## Provenance

Content hash: 1a0f83d314a7ad8d89c66ac1caf76d721ddbf9be0f99b9f83455b26f5f8b7445
Last substantive edit: 2026-10-14
Evidence last checked: 2026-10-14